Suraev, Anastasia
McCartney, Danielle
Marshall, Nathaniel S.
Irwin, Christopher
Vandrey, Ryan
Grunstein, Ronald R.
D’Rozario, Angela L.
Gordon, Christopher
Bartlett, Delwyn
Hoyos, Camilla M.
McGregor, Iain S. http://orcid.org/0000-0002-9307-7159
Funding for this research was provided by:
The Lambert Initiative for Cannabinoid Therapeutics
University of Sydney
Article History
Received: 15 January 2024
Accepted: 15 April 2024
First Online: 17 May 2024
Declarations
:
: ISM is Academic Director of the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically funded research program at the University of Sydney. He has served as an expert witness in various medicolegal cases involving cannabis and has received consulting fees from Medical Cannabis Industry Australia (MCIA) and Janssen. He currently acts as an advisor/consultant to Kinoxis Therapeutics, Psylo and Emyria. He reports research grants and salary support from the Australian National Health and Medical Research Council (NHMRC) and from Lambert Initiative for Cannabinoid Therapeutics. He is an inventor on patents WO2018107216A1 and WO2017004674A1, licensed to Kinoxis Therapeutics involving use of novel small molecules (non-cannabinoid) to treat addictions and social deficits. ISM also has patents WO2020102857A1 and WO2021042178A1 related to use of small molecules (non-cannabinoid) for treating weight gain and opioid withdrawal, as well as patents WO2019227167 and WO2019071302 issued, which relate to cannabinoid therapeutics. CMH (GTN1104003) was supported by Dementia Research Development Fellowships of the Australian National Health and Medical Research Council-Australian Research Council (NHMRC-ARC) and by a National Heart Foundation Future Leader Fellowship. AS was supported by the Australian Government Research Training Program (RTP) and the Vice-Chancellor’s Research Scholarship (VCRS) at the University of Sydney. AS has received consulting fees from the Medical Cannabis Industry Australia (MCIA) and Haleon (consumer healthcare subsidiary of Glaxo Smith-Kline). RRG was supported by NHMRC Senior Principal Research and Investigator Fellowships (GTN1106974/1197439) and has received a speaker fee from Eisai. ALD (NHMRC-ARC Dementia Research Development Fellowship GNT1107716 and NHMRC Emerging Leadership II Investigator Grant GNT2008001). RV has received compensation as a consultant or advisory board member for Jazz Pharmaceuticals, Mira1A Pharmaceuticals, Charlotte’s Web, Canopy Health Innovations, WebMD, and Syqe Medical Ltd. All other authors have no competing financial or non-financial interests to declare. The investigational product was purchased from BOD Australia who were not involved in the conception or design of this study, data analysis (with no access to the data) or the decision to publish. All other commercially available equipment was purchased.